Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16

Guillermo De Velasco, MD at Dana Farber discusses discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC
at ASCO GU 2016